JANX Strangle Strategy
JANX (Janux Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
JANX (Janux Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $891.0M, a beta of 2.57 versus the broader market, a 52-week range of 12.12-35.34, average daily share volume of 1.0M, a public-listing history dating back to 2021, approximately 91 full-time employees. These structural characteristics shape how JANX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.57 indicates JANX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on JANX?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current JANX snapshot
As of May 15, 2026, spot at $13.86, ATM IV 53.40%, IV rank 14.23%, expected move 15.31%. The strangle on JANX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on JANX specifically: JANX IV at 53.40% is on the cheap side of its 1-year range, which favors premium-buying structures like a JANX strangle, with a market-implied 1-standard-deviation move of approximately 15.31% (roughly $2.12 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated JANX expiries trade a higher absolute premium for lower per-day decay. Position sizing on JANX should anchor to the underlying notional of $13.86 per share and to the trader's directional view on JANX stock.
JANX strangle setup
The JANX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With JANX near $13.86, the first option leg uses a $14.55 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed JANX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 JANX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $14.55 | N/A |
| Buy 1 | Put | $13.17 | N/A |
JANX strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
JANX strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on JANX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on JANX
Strangles on JANX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the JANX chain.
JANX thesis for this strangle
The market-implied 1-standard-deviation range for JANX extends from approximately $11.74 on the downside to $15.98 on the upside. A JANX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current JANX IV rank near 14.23% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on JANX at 53.40%. As a Healthcare name, JANX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to JANX-specific events.
JANX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. JANX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move JANX alongside the broader basket even when JANX-specific fundamentals are unchanged. Always rebuild the position from current JANX chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on JANX?
- A strangle on JANX is the strangle strategy applied to JANX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With JANX stock trading near $13.86, the strikes shown on this page are snapped to the nearest listed JANX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are JANX strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the JANX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 53.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a JANX strangle?
- The breakeven for the JANX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current JANX market-implied 1-standard-deviation expected move is approximately 15.31%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on JANX?
- Strangles on JANX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the JANX chain.
- How does current JANX implied volatility affect this strangle?
- JANX ATM IV is at 53.40% with IV rank near 14.23%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.